tetano
Editor, Senior Moderator
J Med Virol
. 2022 Sep 30.
doi: 10.1002/jmv.28190. Online ahead of print.
Development of chemiluminescent lab-on-fiber immunosensor for rapid point-of-care testing of anti-SARS-CoV-2 antibodies and evaluation of longitudinal immune response kinetics following three-dose inactivation virus vaccination
Wenjuan Xu[SUP] 1 [/SUP], Dan Song[SUP] 1 [/SUP], Jiayao Liu[SUP] 1 [/SUP], Xiangzhi Han[SUP] 1 [/SUP], Jiaxin Xu[SUP] 1 [/SUP], Anna Zhu[SUP] 2 [/SUP], Feng Long[SUP] 1 3 [/SUP]
Affiliations
Abstract
Developing reliable, rapid, and quantitative point-of-care testing (POCT) technology of SARS-CoV-2 specific antibodies and understanding longitudinal vaccination response kinetics are highly required to restrain the ongoing Coronavirus Disease 2019 (COVID-19) pandemic. We demonstrate a novel portable, sensitive, and rapid chemiluminescent lab-on-fiber detection platform for detection of anti-SARS-CoV-2 antibodies: the c-LOFI. Using SARS-CoV-2 Spike S1 RBD protein functionalized fiber bio-probe, the c-LOFI can detect anti-SARS-CoV-2 IgG and IgM antibodies with high sensitivity based on their respective HRP labeled secondary antibodies. The limits of detection of anti-SARS-CoV-2 IgG and IgM antibodies were 0.6 ng/mL and 0.3 ng/mL, respectively. The c-LOFI was successfully applied for direct detection of anti-SARS-CoV-2 antibodies in whole blood samples with simple dilution, which can serve as a finger prick test to rapidly detect antibodies. Furthermore, the longitudinal immune response (>12 months) kinetics following three-dose inactivated virus vaccines was evaluated based on anti-SARS-CoV-2 IgG detection results, which can provide importance significance for understanding the immune mechanism against COVID-19 and identify individuals who may benefit from the vaccination and booster vaccination. The c-LOFI has great potential to become a sensitive, low-cost, rapid, high-frequency POCT tool for the detection of both SARS-CoV-2 specific antibodies and other biomarkers. This article is protected by copyright. All rights reserved.
Keywords: Anti-SARS-CoV-2 antibody; Chemiluminescent immunoassay; Immune response kinetics; Lab-on-fiber immunosensor; Vaccination.
. 2022 Sep 30.
doi: 10.1002/jmv.28190. Online ahead of print.
Development of chemiluminescent lab-on-fiber immunosensor for rapid point-of-care testing of anti-SARS-CoV-2 antibodies and evaluation of longitudinal immune response kinetics following three-dose inactivation virus vaccination
Wenjuan Xu[SUP] 1 [/SUP], Dan Song[SUP] 1 [/SUP], Jiayao Liu[SUP] 1 [/SUP], Xiangzhi Han[SUP] 1 [/SUP], Jiaxin Xu[SUP] 1 [/SUP], Anna Zhu[SUP] 2 [/SUP], Feng Long[SUP] 1 3 [/SUP]
Affiliations
- PMID: 36180404
- DOI: 10.1002/jmv.28190
Abstract
Developing reliable, rapid, and quantitative point-of-care testing (POCT) technology of SARS-CoV-2 specific antibodies and understanding longitudinal vaccination response kinetics are highly required to restrain the ongoing Coronavirus Disease 2019 (COVID-19) pandemic. We demonstrate a novel portable, sensitive, and rapid chemiluminescent lab-on-fiber detection platform for detection of anti-SARS-CoV-2 antibodies: the c-LOFI. Using SARS-CoV-2 Spike S1 RBD protein functionalized fiber bio-probe, the c-LOFI can detect anti-SARS-CoV-2 IgG and IgM antibodies with high sensitivity based on their respective HRP labeled secondary antibodies. The limits of detection of anti-SARS-CoV-2 IgG and IgM antibodies were 0.6 ng/mL and 0.3 ng/mL, respectively. The c-LOFI was successfully applied for direct detection of anti-SARS-CoV-2 antibodies in whole blood samples with simple dilution, which can serve as a finger prick test to rapidly detect antibodies. Furthermore, the longitudinal immune response (>12 months) kinetics following three-dose inactivated virus vaccines was evaluated based on anti-SARS-CoV-2 IgG detection results, which can provide importance significance for understanding the immune mechanism against COVID-19 and identify individuals who may benefit from the vaccination and booster vaccination. The c-LOFI has great potential to become a sensitive, low-cost, rapid, high-frequency POCT tool for the detection of both SARS-CoV-2 specific antibodies and other biomarkers. This article is protected by copyright. All rights reserved.
Keywords: Anti-SARS-CoV-2 antibody; Chemiluminescent immunoassay; Immune response kinetics; Lab-on-fiber immunosensor; Vaccination.